|
Mobile version
|
||||||||||||||||||||
Propylthiouracil is an old but useful drug Clinical Thyroidology Share    
Propylthiouracil (6-propyl-2-thiouracil, PTU) is probably one of the oldest drugs on the market in the Western world. Its use as an antithyroid drug has been well established for nearly 70 years. It was originally developed in the search for taste-changing substances. Its goitrogenic effect in laboratory animals led to the detection of its antithyroid effect. In the United States it is currently used as a second-line agent for control of hyperthyroidism and as a first-line agent in pregnancy and routinely by some practitioners. More Thyroid drugs may raise fracture risk in elderly Bloomberg Businessweek Share
Many seniors may be at increased risk for fractures because they take "excessive" doses of drugs used to treat thyroid problems, a new study says. The findings suggest that treatment targets may have to be modified in elderly patients with thyroid problems and that regular dose monitoring of thyroid drugs is essential into older age, the researchers said. More Many children undergo unnecessary screening for thyroid disorders Endocrine Today Share
Nonspecific symptoms such as weight gain, fatigue and failure to thrive often prompt primary care providers to screen for thyroid disorders in children. However, researchers for a new study found that referrals to the pediatric endocrine clinic may not be warranted because most children with abnormal thyroid function tests did not have thyroid pathology identified. More
AstraZeneca launches thyroid cancer drug in US Pharmaceutical Business Review Share
AstraZeneca has launched orphan drug vandetanib, a kinase inhibitor indicated for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable (non-operable) locally advanced or metastatic disease, in the U.S. AstraZeneca is in talks with relevant authorities on a trade name and is currently referring to the treatment by its generic name, vandetanib. More Mammograms pose no risk to thyroid The Times and Democrat Share
The Regional Medical Center has received a number of calls after a recent segment on a television program that questioned how much radiation the thyroid receives from a mammogram. According to a statement released by the American College of Radiology and the Society of Breast Imaging, the radiation dose to the thyroid from a mammogram is extremely low. More |
|
|||||||||||||||||||
|
||||||||||||||||||||||||||||
